Loading...
01/11 11:32
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: strong financial performance with revenue and EBITDA growth, but challenges in Colombia and lack of clear guidance. The Q&A reveals management's cautious stance and reluctance to provide specific forecasts, adding uncertainty. Despite positive financials, the strategic focus on cash flow over growth suggests limited short-term upside. The absence of a shareholder return plan and operational risks in Colombia further temper expectations. Overall, these factors balance out, leading to a neutral stock price prediction.
Adjusted EBITDA Growth (Q4 2024) 28% FX neutral growth year-over-year, driven by operational efficiencies and improved service mix.
Adjusted EBITDA Margin (Q4 2024) Margin expanded 3.1 percentage points year-over-year, reflecting strong operational performance.
Revenue Growth (Q4 2024) 11% growth on an FX neutral basis, reaching approximately PEN 1.1 billion, led by Peru and Mexico.
Full Year Revenue (2024) PEN 4.4 billion, 12% higher than 2023 on an FX neutral basis.
Net Income (Q4 2024) PEN 124 million, a gain of PEN 338 million from a net loss of PEN 214 million in 2023.
Adjusted Net Income (Q4 2024) Positive PEN 36 million, compared to negative PEN 6 million in Q4 2023.
Cash Position (End of 2024) PEN 236 million, an 18% sequential increase from Q3 2024.
Net Cash from Operating Activities (2024) Increased 15% year-over-year to PEN 668 million.
Free Cash Flow (2024) Generated PEN 432 million, with organic free cash flow rising 18% compared to 2023.
Debt Leverage Ratio (End of 2024) Fell to 3.6 times, almost a full turn below the previous year.
Interest Expenses (Q4 2024) Decreased 63% year-over-year, primarily due to refinancing costs in Q4 2023.
Operating Profit (2024) Increased 40% to PEN 223 million, including a reversal of holdback obligations.
Tax Expenses (2024) Decreased by PEN 30 million or 34%, due to normalization of the effective tax rate.
Oncology Membership Growth (2024) Increased 1.6% year-over-year.
Capacity Utilization (Q4 2024) Increased 2.6 percentage points to 66%.
Oncology MLR (Q4 2024) Decreased 0.7 percentage points to 53%.
CapEx (2024) PEN 160 million, representing 3.7% of revenues, mainly for maintenance and infrastructure.
Oncology Agreement: Signed a five-year exclusivity agreement with eight leading oncologists in Monterrey, positioning Auna as the oncology player of reference in the region.
Onco Salud Expansion: Continued growth in plan memberships, with a 7.4% increase in overall memberships and 1.6% in oncology memberships for the year.
Market Expansion in Mexico: Auna is deploying its integrated healthcare model in Mexico, targeting the underpenetrated private healthcare market.
B2B and B2B2C Segments: Developing B2B and B2B2C segments in Mexico to gain scale and access policyholders outside Monterrey.
Operational Efficiency: Achieved 28% FX neutral adjusted EBITDA growth in Q4, with margin expansion of 3.1 percentage points year-over-year.
Cash Flow Management: Prioritizing cash flow over growth in Colombia, focusing on risk-sharing models to enhance cash conversion.
Strategic Shift in Colombia: Limiting risk exposure in Colombia by calibrating growth and focusing on preserving cash flow.
Long-term Growth Strategy: Expecting Mexico to become a larger contributor to growth as operations scale and high complexity services are prioritized.
Regulatory Issues: The company faces challenges in Colombia due to government interventions affecting healthcare providers, which have led to a cautious approach in managing growth and cash flow.
Supply Chain Challenges: There are ongoing issues with payer relationships in Colombia, particularly with Nueva Epe S.A., which has resulted in the company limiting its risk exposure and focusing on cash generation.
Economic Factors: The economic environment in Colombia is uncertain, impacting the company's ability to provide guidance for growth in 2025, particularly due to external factors beyond their control.
Competitive Pressures: The company is working to establish partnerships with insurers and expand its market share in Monterrey, Mexico, amidst a competitive healthcare landscape.
Operational Risks: The company is phasing out services for certain payers in Colombia to manage risk, which may affect revenue stability in the short term.
Cash Flow Management: The company is prioritizing cash flow over growth in Colombia, which may limit operational capacity and affect overall performance.
2024 Milestones Achieved: Auna achieved all 2024 milestones, including a 20% FX neutral EBITDA growth target.
Growth in Mexico: Auna is deploying its business model in Mexico, focusing on high complexity services and operational efficiency.
Oncology Agreement: Auna signed a five-year exclusivity agreement with leading oncologists in Monterrey to enhance its oncology services.
Colombia Strategy: Auna is limiting risk exposure in Colombia while maintaining a focus on cash flow and exploring growth opportunities.
Expansion Plans: Auna plans to expand its footprint in Mexico and develop B2B and B2B2C segments.
2025 Revenue Expectations: Auna expects continued growth momentum in 2025, particularly in Mexico and Peru.
2025 EBITDA Growth Target: Auna aims for a 20% adjusted EBITDA growth internally, but is cautious about providing formal guidance due to uncertainties in Colombia.
Debt Leverage Target: Auna aims to achieve a medium-term target of a 3x leverage ratio.
CapEx for 2024: Auna's CapEx for 2024 was $160 million, primarily for maintenance and infrastructure.
Cash Flow Expectations: Auna anticipates improved cash flow management through risk-sharing models in Colombia.
Shareholder Return Plan: Auna has not explicitly mentioned a shareholder return plan involving dividends or share buybacks during the call. However, they have indicated a focus on maintaining a positive cash flow and improving their credit profile, which may indirectly support future shareholder returns.
The earnings call summary highlights strong growth in Peru and Colombia, strategic partnerships like the one with Sojitz, and expansion plans in Mexico. Despite some concerns about Mexico's revenue decline and system integration delays, the positive outlook on market recovery, margin improvements, and strategic investments suggest a positive sentiment. The Q&A section reinforced this with optimism about growth opportunities, despite some uncertainties in guidance. Overall, the positive aspects, especially the Sojitz partnership and expansion plans, outweigh the negatives, indicating a likely positive stock price reaction.
The earnings call presents a mixed picture. Positive aspects include revenue growth in Mexico and OncoSalud, improved EBITDA in Colombia, and strong adjusted net income. However, concerns include flat revenue in Colombia, decreasing cash position, and vague management responses about growth in Mexico. The Q&A revealed optimism about margin maintenance and risk-sharing in Colombia, but also highlighted ongoing challenges in Mexico. Given these mixed signals and lack of a market cap, a neutral stock price movement is expected.
The earnings call presents mixed signals: strong financial performance with revenue and EBITDA growth, but challenges in Colombia and lack of clear guidance. The Q&A reveals management's cautious stance and reluctance to provide specific forecasts, adding uncertainty. Despite positive financials, the strategic focus on cash flow over growth suggests limited short-term upside. The absence of a shareholder return plan and operational risks in Colombia further temper expectations. Overall, these factors balance out, leading to a neutral stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
